PA
VCEL icon

PharVision Advisers’s Vericel Corp VCEL Stock Holding History

PharVision Advisers’s Portfolio VCEL Stock Details VCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,949
Closed -$394K – 625
2025
Q4 		$394K Buy
+10,949
New +$402K 0.2% 131

Other funds holding VCEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

PharVision Advisers's VCEL Position: Q1 2026 in Review

PharVision Advisers sold out of Vericel Corp (VCEL) in Q1 2026, closing a stake of 10,949 shares — an estimated $394K sold.

PharVision Advisers first reported a position in VCEL in Q4 2025 and held it in 1 quarter. The position peaked at $394K in Q4 2025. 279 funds tracked by Wall St. Rank hold VCEL as of Q1 2026.

  • PharVision Advisers reported no remaining Vericel Corp position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 10,949 Vericel Corp shares in Q1 2026, an estimated $394K.
  • PharVision Advisers first reported a position in Vericel Corp in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Vericel Corp position peaked at $394K in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Vericel Corp as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.